The Collective has secured a grant from the SOAS Anti-Corruption Evidence research consortium (SOAS-ACE) to undertake research on private sector corruption. The project focuses on Pakistan's pharmaceutical sector, which is currently valued at approximately USD$3 billion and comprises more than 750 firms. Corruption in the pharmaceutical sector in Pakistan has multiple negative impacts on development. It inhibits growth and dynamism in the economy - as an illustration, we compare Pakistan's export performance with Jordan and India and find Pakistan lagging far behind. Moreover, corruption also leads to higher out-of-pocket expenditures for consumers as well as putting pressure on health care services through repeat patients stretching scarce resources. The research project will examine different facets of corruption in this sector in order to find feasible anti-corruption strategies that increase the quality of available pharmaceuticals and encourage a dynamic economic sector.